2nd International Symposium on Inner Ear Therapeutics

4-6 November 2019 • Hanover, Germany

2nd International Symposium on Inner Ear Therapeutics

4-6 November 2019 • Hanover, Germany

Congress details

Print-File

Scientific programme

8:15-10:00 Introduction, welcome note and keynote lectures
Chairs: T. Lenarz and A. Warnecke (Hanover/DE)
8:30-8:45 State of the art: Inner ear therapies - Where we are
T. Lenarz (Hanover/DE)
8:45-9:20 Keynote 1: MICROCIRCULATORY DISORDERS AS A BASIC INITIATOR OF DEGENERATIVE DISEASE 
A. Haverich; (Hanover/DE)
9:20-10:00 Keynote 2:  ADENO-ASSOCIATED VIRUS (AAV) VECTORS – HOW  TO OPTIMIZE A SMART VIRUS FOR IN VIVO GENE THERAPY
H. Büning (Hanover/DE)
10:00-10:30 Break (30 min)
10:30-11:45


10:30-10:45



10:45-11:15


11:15-11:45
Session 1: Proteomics, biomarkers and neuroinflammation
Chairs: A. Szczepek (Berlin/ DE), A. Warnecke (Hanover/DE)

AT1
TLR4 and MyD88 Activation of TRPV1 Modulates Cellular Uptake of Aminoglycosides
F. Taghizadeh, M. Jiang, W. Meier, P. Steyger (Omaha, NE/US, Portland, OR/US)

Keynote 3A: EVS AS NOVEL TRANSLATIONAL INNER EAR THERAPEUTICS
E. Rohde (Salzburg, AT)

Keynote 3B: MANUFACTURING ASPECTS FOR CELL BASED-THERAPEUTICS
M. Gimona (Salzburg, AT)
11:45-12:45 Lunch (60 min)
12:45-13:50 Session 2: Clinical genetics
Chairs: S. Saffieddine (Paris/FR) and V. van Rompaey (Antwerpen/BE)
12:45-13:15 Highlight talk: PROGRESSIVE ADULT-ONSET SENSORINEURAL HEARING LOSS: CHALLENGES AND OPPORTUNITIES FOR INNOVATIVE THERAPIES
V. van Rompaey (Antwerpen/BE)
13:15-13:35


13:35-13:50
Clinical Genetics on « Presbycusis Genetics Landscape »
C. Petit (Paris/FR)

AT2
Acsl4 mutation leads to early and fast progressive hearing loss in mice
E. Martelletti (London/GB), N. Ingham (Hinxton, Cambridge/GB, London/GB), R. Colas, J. Dalli (London/GB), K. Steel (Hinxton, Cambridge/GB, London/GB)
13:50-15:20 Session 3: Neurotrophins, small molecules and modes of delivery
Chairs: M. Knipper (Tübingen/DE), T. Thum (Hanover/DE)
13:50-14:30 Keynote 4: SMALL MOLECULES CLINICAL TRIAL FOR MENIÈRES DISEASE
J. Kil (Seattle, WA/US)
14:30-15:00


15:00-15:15
Highlight talk: LncRNA AS NOVEL THERAPEUTIC TARGETS
T. Thum (Hanover/DE)

AT3

Engraftment of Human Pluripotent Stem Cell-Derived Otic Progenitors in the Damaged Adult Cochlea
A. Zine (Montpellier/FR), A. Lopez-Juarez (Guanajuato/MX), H. Lahlou (Boston, MA/US), C. Ripoll (Montpellier/FR), A. Edge (Boston, MA/US)
15:15-15:45 Break (30 min)
15:45-17:00 Session 4: Cohorts and Biobanking
Chairs: A. Lesinski-Schiedat, T. Illig (Hanover/DE)
15:45-16:00 AT9
Developing precision medicine for sensorineural hearing loss: learning from existing cohorts.
P. Sethukumar, R. Mandavia, N. Mehta, O. Yildirim (London/GB), E. Stragier, M. J. Duran (Paris/FR), C. Santos, A. Schilder (London/GB)
16:00-16:15 AT5
Can we develop a National Comprehensive Cohort of patients with hearing loss?
N. Mehta, A. Schilder (London/GB)
16:15-16:30 AT6
Genotype-Phenotype Studies are Important for the Evaluation of Molecular Inner Ear Therapies
R. Pennings, C. Lanting, J. Smits, M. Wesdorp, S. Robijn, I. Feenstra, E. M. Pool, H. Kremer, H. Yntema (Nijmegen/NL)

 16:30-16:45

AT8
Prognostic factors for outcomes of idiopathic Sudden onset Sensorineural Hearing Loss: the SeaSHeL UK prospective cohort study
R. Mandavia, SeaSHel Collaborative (London/GB)

16:45-17:00

AT4
Clinical next-generation sequencing database of deafness: unified management tool of clinical and genetic information.
S. Y. Nishio, S. I. Usami (Matsumoto/JP)

17:00-18:30 Session 5: Local drug-delivery
Chairs: N. Prenzler (Hanover/DE), F. F. Telischi (Miami, FL)
17:00-17:15 AT28 former P8
In Vivo Assessment of Dexamethasone (DXM) Infused and Coated Poly(lactic-co-glycolic acid) (PLGA) Microneedles as an Improved Drug Delivery System for Intracochlear Biodegradable Devices
D. Pawley, S. Goncalves, E. Bas, E. Dikici, S. Deo, S. Daunert, F. F. Telischi (Miami, FL/United States)
17:15-17:30 AT29 former P1
Local drug delivery based on a particulate chitosan gel — a preclinical study
G. Laurell, P. Videhult Pierre, P. Damberg, M. Kisiel (Uppsala/SE), S. Nikkhou Aski (Stockholm/SE), M. Andersson (Södertälje/SE), L. Hällgren (Södertälje/SE), A. Fransson (Stockholm/SE)  
17:30-17:45 AT30 former P5
Targeted Delivery of Drugs to the Otic Compartment: Preclinical and Clinical Experience
F. Piu, X. Wang, R. Fernandez, N. Tsivkovskaia, S. Coleman, T. Altmann, J. Hou (San Diego, CA/US)
17:45-18:00




18:00-18:15
AT31 former P2
Long-term effects and potential limits of intratympanic dexamethasone-loaded hydrogels combined with dexamethasone-eluting cochlear electrodes in a guinea pig model
N. Ahmadi, J. C. Gausterer , C. Honeder, C. Arnoldner (Vienna/AT)

AT32 former P9
Silicone matrices for controlled drug delivery to the inner ear: Effects of combining dexamethasone and dexamethasone sodium phosphate
A. Qnouch, V. Solarczyk, J. Verin, C. Vincent, F. Siepmann, J. Siepmann (Lille/FR)
18:15-18:30 FX-322, a cochlear progenitor cell activator as a potential therapy for sensorineural hearing loss
C. LeBel, W. McLean (Woburn, MA/US)
18:30-20:00 Welcome reception at posters
20:30 Speakers Dinner (on invitation only) 

8:30-10:00 Session 6: miRNA and epigenetics
Chairs: H. Staecker (Kansas City, KS/US), J. Schulze (Hanover/DE)
8:30-9:10 Keynote 5: STEM CELL-DERIVED ORGANOIDS AS A HUMANIZED MODEL FOR CONGENITAL INNER EAR DISORDERS
E. Hashino (Indianapolis, IN/US)
9:10-9:40    


9:40-10:00
Highlight talk: GENE ELECTROTRANSFER VIA THE COCHLEAR IMPLANT ELECTRODE
G. Housley (Sydney, AU)

AT10
The orchestration of hearing: the epigenetic landscape of the inner ear
S.Taiber (Tel Aviv/IL)
10:00-11:00 Break at Posters (60 min)
11:00-12:15 Session 7: Bionic and biohybrid devices
Chairs: T. Lenarz, (Hanover/DE), A. Raji (Marrakech/MA)
11:00-11:30 Highlight talk: CLINICAL APPROACHES FOR IMPROVED WOUND HEALING
E. Lewis (Beersheba/IL)
11:30-11:45   AT11
Cochlear optogenetics by ultrafast optogenetic stimulation of the auditory pathway
V. Rankovic, D. Keppeler, B. Bali, D. Lopez de la Morena, T. Mager, A. Huet, T. Moser (Göttingen/DE)  
11:45-12:00   AT12
The improvement of the human hearing capacity with Low Level Laser Therapy (LLLT) -
a look back over 25 years of clinical experiences.
L. Wilden (Jesus, Ibiza/ES)  
12:00-12:15     AT13
Reproducible and long term efficacy of a new neuromodulation treatment for Tinnitus evaluated in over 500 participants
B. Langguth (Regensburg/DE), C. Hamilton, S. Hughes, E. Meade ( Dublin/IR), M. Schecklmann (Regensburg/DE), T. Subramaniam (Dublin/IR), S. Vanneste (Dublin/IR, Dallas, TX/US), D. Hall (Nottingham/GB), B. Conlon (Dublin/IR), H. Lim (Minneapolis, MN/US, Dublin/IR)  
12:15-13:15 Lunch (60 min)
13:15-15:30 Session 8: Gene therapy
Chairs: L. Lustig (New York, NY/US), J. Holt (Boston, MA/US), H. Büning (Hanover, DE)
13:15-13:45    
13:45-14:15
Keynote 6: Lentiviral Vectors: A large capacity vectorization approach to the inner ear?
A. Schambach, (Hanover, DE)
Keynote 7: GENOME EDITING: HOW FAR FROM CLINICS
Z.-Y. Chen (Boston, MA/US)
14:15-14:30   AT14
CRISPR/Cas9-mediated targeted Y chromosome elimination in the mammalian auditory system
Y. Tao, H. Wu, X. Zhao, Z. Sun, T. Dong (Shanghai/CN)
14:30-14:45   AT15
Exploring regulatory networks of miR-96 to identify therapeutic targets for progressive hearing loss
M. Lewis, M. A. Moreno Pelayo, K. Steel (London/GB)
14:45-15:00   AT16
Development of a mutant-allele specific genetic therapy for DFNA9
E. de Vrieze,  J. Peijnenborg, H. Kremer, E. van Wijk (Nijmegen/NL)
15:00-15:15   AT17
Gene therapy rescues inner hair cell synaptic function and hearing in synaptosomal-associated protein-25 deficient mice
C. Calvet, G. Lahlou, T. Peineau, C. Trébeau, S. Nouaille, J. Boutet de Monvel, A. Lelli, V. Michel, N. Michalski (Paris/FR), P. Avan (Clermont-Ferrand/FR), C. Petit (Paris/FR), D. Dulon (Bordeaux/FR), S. Safieddine (Paris/FR)
15:15-15:30 AT34 former P17
Template-free genome editing profiles are biased in postmitotic hair cells
L. Liu, W. Xiong (Beijing/CN)
15:30-16:00 Break at posters (30 min)
16:00-16:30   Session 8: Gene therapy (continued),
Chairs: B. Mazurek (Berlin/DE), L. Song (Shanghai/CN)
  16:00     Highlight talk: EPIGENETICS OF DEVELOPMENT AND THE FAILURE OF REGENERATION IN THE MAMMALIAN INNER EAR
N. Segil (Los Angeles CA/US )  
16:30-16:45 AT27
Tailored AAV-based transgene expression in the inner ear with cell-type specific promoters
M. Schwander (Boston, MA/US), X. Wu, Liu, S., Cancelarich (Tarrytown, NY/US), G. Pregernig, F. Shi, K.So, (Boston, MA/US), L.Sabin, M. Drummond (Boston, MA/US), N. Pan, J. Whitton, A. Palermo, J. Burns (Boston, MA/US)  
16:45-17:30   Session 9: Site of lesion diagnostics and in vivo imaging
Chairs: B. Mazurek (Berlin, DE), L. Song (Shanghai/CN)
16:45-17:00   AT19
The need for a deep phenotype of hearing loss to guide inner ear therapy: understanding speech-in-noise and the underlying site-of-lesion.
C. Lanting (Nijmegen/NL), J. Leijendekkers (Zwolle/NL), A. Bosman, A. Snik, R. Pennings (Nijmegen/NL)
17:00-17:15 AT20
Effects of cochlear implantation on microvascular permeability in the cochlear lateral wall
B. P. Ernst, S. Siemer, D. Wünsch, U. R. Heinrich, R. H. Stauber, S. Strieth (Mainz/DE)
17:15-17:30    AT21
Effects of Local Cochlear Lesions at Peripheral Dendrites or Somata of Spiral Ganglion Neurons on Electrophysiological Markers
W. Konerding (Hanover/DE), J. Arenberg (Boston, MA/US), A. Kral, P. Baumhoff (Hanover/DE)  
17:30-17:45 AT 33 former P3
Interest of cochlear transparency associated with confocal laser scanning microscopy and light sheet microscopy for three-dimensional cochlear visualization and tissue damage after implantation.
P. E. Lemesre, M. Risoud, M. Tardivel, J. Siepmann, C. Vincent (Lille/FR)  
17:45-19:00 ISIET Board Meeting (founding members only)
20:00 Social evening
at the restaurant "Meiers Lebenslust"
Osterstrasse 64, 30159 Hanover
8:30-10:25 Session 10: Cell-based approaches including regeneration
Chairs: Y.-C. Hsu (Taipei/TW), A. Schambach (Hanover/DE)
8:30-9:10 Keynote 6: "THE FAST AND THE CURIOUS – HIGH-THROUGHPUT IN VITRO AND IN VIVO INTERROGATION OF AAV CAPSID LIBRARIES"
D. Grimm (Heidelberg, DE)
9:10-9:40 Highlight talk: LOCAL DRUG DELIVERY: APPLICATION MODES AND CLINICAL FEASIBILITY
S. Plontke (Halle/DE)  
9:40-9:55 AT22
Combined BDNF and NT-3 growth factor treatment boosts neurite outgrowth in an adult-like postnatal day 7 murine in vitro spiral ganglion explant model
H. Löwenheim, M. Müller, S. Fink (Tübingen/DE)  
9:55-10:10 AT23
CRISPR-on system for the activation of endogenous human ATOH1, POU4F3, SOX2 and inner ear genes: bases for a possible cell replacement therepy in hearing loss
G. Perez Raffo, L. Vigezzi, C. Fagundez,, C. Giménez, C. Boccio, F. Pereyra-Bonnet (Buenos Aires/AR)  
10:10-10:25 AT24
Application of mesenchymal stem cells and extracellular vesicles in restoring the cisplatin-induced hearing loss and rescuing the loss of cochlear hair cells in mice
Y. C. Hsu (Taipei/TW)
10:25-11:00 Break at posters (35 min)
11:00-12:35 Session 11: Outcome measures and clinical trials
Chairs: A. G. M. Schilder (London/GB), R. Salcher (Hanover/DE) requested
11:00-11:30 Highlight talk: PROTECTION FROM CISPLATIN TOXICITY
K. Rajput (London/GB)
11:30-11:50 Trials, training, networks in inner ear therapeutics. Where do we go from here?
A. G. M. Schilder (London/GB)  
11:50-12:10AT25
Oral SENS-401 Reduces Central Auditory Neuronal Loss after Acoustic Trauma in NMRI Mice
S. Voigt, M. Gröschel, D. Basta, A. Ernst (Berlin/DE), J. Dyhrfjeld-Johnsen (Montpellier/FR)
12:05-12:20 AT26
Development of ORC-13661: A Medicine to Prevent Aminoglycoside-Induced Ototoxicity
D. Raible, E. Rubel, J. Simon, V. Groppi, G. Johnson, M. Gleser (Seattle, WA/United States)
12:20-12:35 State of the art - inner ear therapies: Where will we go
A. Warnecke (Hanover/DE)
12:35 Farewell
For those who are interested, registration requested)
14:00-16:00 Post conference tour
14:00-16:00 INNER EAR LABS: Guided Tour through NIFE (Lower Saxony Centre for Biomedical Engineering, Implant Research and Development)